Canada's Reactionary Response to Trump
25 August 2026
North America
When Donald Trump moved against gender-identity policies in the United States, Canada's response was to entrench its own position rather than follow the evidence. This episode examines how political opposition to one administration can drive healthcare and social policy in another country — and why the contrast with the UK's evidence-led Cass Review process matters for understanding where gender medicine goes next.
Donald Trump's return to the White House brought a sharp reorientation of federal policy on gender identity in the United States. Executive orders reversed transgender military service, ended federal recognition of non-binary categories, and signalled a broader rollback of gender-affirming care in publicly funded settings. The political effect was immediate and global: governments and institutions that had championed those policies found themselves under pressure to define their positions. Canada's response, as this episode explores, was to lean in rather than reconsider. Rather than treating the political moment as an opportunity to review the evidence base for gender-affirming interventions — particularly for children and adolescents — Canadian institutions appeared to double down, framing any critical examination of the field as alignment with Trumpism. The effect was to make scepticism politically toxic at precisely the moment when an independent review might have been most valuable. This dynamic matters far beyond Canada's borders. When opposition to one political figure becomes the organising principle of healthcare policy, the question of what the evidence actually shows tends to get lost. The Beyond Gender hosts examine how a country's ideological reaction to an external political threat can freeze debate, punish dissent within clinical and academic communities, and entrench practices that are coming under serious scrutiny elsewhere. The United Kingdom's trajectory offers a pointed contrast. The independent Cass Review, published in April 2024, concluded that the evidence base for puberty blockers and cross-sex hormones in children and young people was remarkably weak. NHS England acted on that finding, stopping puberty blocker prescriptions to new patients in paediatric gender services and commissioning new research. The process was led by a clinician, grounded in systematic evidence review, and — crucially — insulated from the charge that it was driven by any particular government's ideology. That insulation is precisely what Canada appears to lack, according to the discussion in this episode. When reform becomes associated with a polarising foreign leader, those arguing for a more cautious clinical approach can be dismissed as political fellow-travellers rather than heard as evidence-based critics. The episode raises a question that will resonate with audiences watching other countries navigate this terrain: what happens to children when a government's priority is to signal its values rather than follow the science? The UK's Cass Review process demonstrates that rigorous, independently led inquiry can reach difficult conclusions and translate them into policy change — without those conclusions being weaponised in a culture war.
